Regeneron Pharmaceuticals, Inc.  (REGN) has reported a 63.31 percent jump in profit for the quarter ended Dec. 31, 2016. The company has earned $253.12 million, or $2.19 a share in the quarter, compared with $154.99 million, or $1.34 a share for the same period last year. On the other hand, adjusted net income for the quarter stood at $352.54 million, or $3.04 a share compared with $257.75 million or $2.23 a share, a year ago.

Revenue during the quarter grew 11.73 percent to $1,226.83 million from $1,098.08 million in the previous year period. Gross margin for the quarter expanded 401 basis points over the previous year period to 93.91 percent. Total expenses were 71.72 percent of quarterly revenues, down from 78.96 percent for the same period last year. This has led to an improvement of 724 basis points in operating margin to 28.28 percent.

Operating income for the quarter was $347 million, compared with $231.08 million in the previous year period.

"The hard work of our scientists over the last decades has brought Regeneron to the next phase of our evolution - this year we anticipate launching two additional important therapies, significantly expanding our impact for patients with serious diseases and our company's growth potential," said Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer of Regeneron. "In March, we look forward to the potential U.S. approval of Dupixent, our innovative and breakthrough IL4/13 blocking antibody, in adults with atopic dermatitis. We believe Dupixent may have the potential to help additional patients with serious allergic diseases, with pivotal Phase 3 data in adult asthma patients expected later this year. We are also studying Dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis."